EMA Withdrawn: Gefitinib Mylan (gefitinib) — Mylan Pharmaceuticals Limited

View source ↗

Summary

The European Medicines Agency has withdrawn Gefitinib Mylan (gefitinib) from regulatory authorization. It was indicated for non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gefitinib Mylan (Gefitinib)

Snippet

Status: Withdrawn. Therapeutic area: Carcinoma, Non-Small-Cell Lung. MAH: Mylan Pharmaceuticals Limited. Decision date: 23/06/2023